Abstract
ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global participation has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report, our 17th report, is a part of a series published over the past 2 years. Data have been entered for 800,459 individuals from 1701 partner institutions and networks across 60 countries.
The comprehensive analyses detailed in this report includes hospitalised individuals of all ages for whom data collection occurred between 30 January 2020 and up to and including 5 January 2022, AND who have laboratory-confirmed SARS-COV-2 infection or clinically diagnosed COVID-19.
For the 699,014 cases who meet eligibility criteria for this report, selected findings include:
median age of 58 years, with an approximately equal (50/50) male:female sex distribution
29% of the cohort are at least 70 years of age, whereas 4% are 0-19 years of age
the most common symptom combination in this hospitalised cohort is shortness of breath, cough, and history of fever, which has remained constant over time
the five most common symptoms at admission were shortness of breath, cough, history of fever, fatigue/malaise, and altered consciousness/confusion, which is unchanged from the previous reports
age-associated differences in symptoms are evident, including the frequency of altered consciousness increasing with age, and fever, respiratory and constitutional symptoms being present mostly in those 40 years and above
16% of patients with relevant data available were admitted at some point during their illness into an intensive care unit (ICU), which is slightly lower than previously reported (19%)
antibiotic agents were used in 35% of patients for whom relevant data are available (669,630), a significant reduction from our previous reports (80%) which reflects a shifting proportion of data contributed by different institutions; in ICU/HDU admitted patients with data available (50,560), 91% received antibiotics
use of corticosteroids was reported in 24% of all patients for whom data were available (677,012); in ICU/HDU admitted patients with data available (50,646), 69% received corticosteroids
outcomes are known for 632,518 patients and the overall estimated case fatality ratio (CFR) is 23.9% (95%CI 23.8-24.1), rising to 37.1% (95%CI 36.8-37.4) for patients who were admitted to ICU/HDU, demonstrating worse outcomes in those with the most severe disease
To access previous versions of ISARIC COVID-19 Clinical Data Report please use the link below: https://isaric.org/research/covid-19-clinical-research-resources/evidence-reports/
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
This work was made possible by the UK Foreign Commonwealth and Development Office; Wellcome [215091/Z/18/Z] [205228/Z/16/Z] [220757/Z/20/Z]; Bill & Melinda Gates Foundation [OPP1209135]; UK Medical Research Council Clinical Research Training Fellowship MR/V001671/1; the philanthropic support of the donors to the University of Oxfords COVID19 Research Response Fund (0009109); CIHR Coronavirus Rapid Research Funding Opportunity OV2170359 and the coordination in Canada by Sunnybrook Research Institute; endorsement of the Irish Critical Care Clinical Trials Group coordination in Ireland by the Irish Critical Care Clinical Trials Network at University College Dublin and funding by the Health Research Board of Ireland [CTN 2014 12]; the Rapid European COVID 19 Emergency Response research (RECOVER) [H2020 project 101003589] and European Clinical Research Alliance on Infectious Diseases (ECRAID) [965313]; the COVID clinical management team AIIMS Rishikesh India; the COVID 19 Clinical Management team Manipal Hospital Whitefield Bengaluru India; Cambridge NIHR Biomedical Research Centre; the dedication and hard work of the Groote Schuur Hospital Covid ICU Team; support by the Groote Schuur nursing and University of Cape Town registrar bodies coordinated by the Division of Critical Care at the University of Cape Town; the Liverpool School of Tropical Medicine and the University of Oxford; the dedication and hard work of the Norwegian SARS CoV 2 study team; the Research Council of Norway grant no 312780 and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner; Imperial NIHR Biomedical Research Centre; the Comprehensive Local Research Networks (CLRNs) of which PJMO is an NIHR Senior Investigator (NIHR201385); Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 115523 COMBACTE resources of which are composed of financial contribution from the European Unions Seventh Framework Programme (FP7/2007 2013) and EFPIA companies in kind contribution; the French COVID cohort (NCT04262921) is sponsored by INSERM and is funded by the REACTing (REsearch & ACtion emergING infectious diseases) consortium and by a grant of the French Ministry of Health (PHRC n 20 0424); Stiftungsfonds zur Forderung der Bekampfung der Tuberkulose und anderer Lungenkrankheiten of the City of Vienna Project Number: APCOV22BGM; Italian Ministry of Health Fondi Ricerca corrente L1P6 to IRCCS Ospedale Sacro Cuore Don Calabria; Australian Department of Health grant (3273191); Gender Equity Strategic Fund at University of Queensland Artificial Intelligence for Pandemics (A14PAN) at University of Queensland the Australian Research Council Centre of Excellence for Engineered Quantum Systems (EQUS CE170100009) the Prince Charles Hospital Foundation Australia; grants from Instituto de Salud Carlos III Ministerio de Ciencia Spain; Brazil National Council for Scientific and Technological Development Scholarship number 303953/2018 7; the Firland Foundation Shoreline Washington USA; a grant from foundation Bevordering Onderzoek Franciscus; the South Eastern Norway Health Authority and the Research Council of Norway; Institute for Clinical Research (ICR) National Institutes of Health (NIH) supported by the Ministry of Health Malaysia; and preparedness work conducted by the Short Period Incidence Study of Severe Acute Respiratory Infection. This work uses data provided by patients and collected by the NHS as part of their care and support #DataSavesLives. The data used for this research were obtained from ISARIC4C. We are extremely grateful to the 2648 frontline NHS clinical and research staff and volunteer medical students who collected these data in challenging circumstances; and the generosity of the patients and their families for their individual contributions in these difficult times. The COVID 19 Clinical Information Network (CO CIN) data was collated by ISARIC4C Investigators. Data and Material provision was supported by grants from: the National Institute for Health Research (NIHR; award CO CIN 01) the Medical Research Council (MRC; grant MC PC 19059) and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE) (award 200907) NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927) Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153) NIHR Biomedical Research Centre at Imperial College London (award IS BRC 1215 20013) and NIHR Clinical Research Network providing infrastructure support. We also acknowledge the support of Jeremy J Farrar and Nahoko Shindo.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee approval for this work was given by the World Health Organisation Ethics Review Committee (RPC571 and RPC572 on 25 April 2013). Institutional approval was additionally obtained by participating sites including the South Central Oxford C Research Ethics Committee in England (Ref 13/SC/0149) and the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the United Kingdom and the Human Research Ethics Committee (Medical) at the University of the Witwatersrand in South Africa as part of a national surveillance programme (M160667) collectively representing the majority of the data. Other institutional and national approvals are in place as per local requirements.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* group members, participating institutions and funders are listed at end of the report
This is an updated version of ISARIC COVID-19 Clinical Data Report: 27 March 2022 This version includes many new charts and visualisations, as well as data on an additional ∽100,000 individuals reflecting the evolving nature of the pandemic.
Data Availability
We welcome applications for access to data on the COVID-19 Data Sharing Platform via the Data Access Committee (https://www.iddo.org/covid-19).
